Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (6): 1069-1074. doi: 10.19723/j.issn.1671-167X.2020.06.013

Previous Articles     Next Articles

Clinical features of hydronephrosis induced by retroperitoneal fibrosis: 17 cases reports

Shi-bo LIU1,Hui GAO2,Yuan-chun FENG3,Jing LI4,Tong ZHANG5,Li WAN6,Yan-ying LIU7,Sheng-guang LI2,Cheng-hua LUO1,(),Xue-wu ZHANG7,()   

  1. 1. Department of Retroperitoneal Tumor Surgery
    2.Department of Rheumatology and Immunology
    3. Department of Radiology
    4. Department of Laboratory Medicine
    5. Department of Pathology
    6. Department of Nephrology, Peking University International Hospital, Beijing 102206, China
    7. Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing 100044, China
  • Received:2020-07-31 Online:2020-12-18 Published:2020-12-13
  • Contact: Cheng-hua LUO,Xue-wu ZHANG E-mail:luochenghua@pkuih.edu.cn;xuewulore@163.com
  • Supported by:
    Peking University International Hospital Research Grant(YN2019QN02)

Abstract:

Objective: To investigate the clinical features and outcome of hydronephrosis induced by retroperitoneal fibrosis (RPF), and to evaluate the effect of corticosteroid based therapy combined with surgical intervention of ureteral obstruction. Methods: A total of 17 RPF patients with hydronephrosis hospitalized in Peking University International Hospital from May 2016 to December 2019 were analyzed retrospectively. Results: The median age was 56 (53, 65) years, the male to female ratio was 2.4:1, and the disease duration was 4.00 (0.83, 8.00) months. The initial symptoms included back pain (9 cases), abdominal pain (6 cases), oliguria (2 cases) and lower limb edema (3 cases). Eight patients presented left hydronephrosis, 1 right hydronephrosis and 8 bilateral hydronephrosis. C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) were both elevated in 13 patients (76.5%, n=17). Immunoglobin (Ig) G4 increased in 5 cases (29.4%, n=17). IgG, IgE and IgA increased in 4 cases (30.8%, n=13), 4 cases (30.8%, n=13) and 1 case (7.7%, n=13), respectively. Among 12 patients who underwent biopsy, 3 patients were diagnosed with IgG4-relate disease. The level of IgG4 in the tissues varied, 6 cases expressed less than 10 per high power field (HPF) or no expression (50.0%). Only 2 cases expressed 10-30/HPF (16.7%), and 4 cases revealed more than 30/HPF (33.3%). Among the 17 patients with ureteral obstruction, no urinary drainage procedure was needed in 4 patients who had mild ureteral obstruction, whereas, ureteral stenting was carried out in the other 13 cases before drug treatment. Time was too short to evaluate the effect of urinary drainage procedures in 4 patients. For the rest, ureterolysis had to be performed in 3 cases after failed ureteral stent insertion. Successful drain removal was accomplished in all of these 9 patients and the mean time to drain removal was (6.7±3.0) months. In addition, 10 patients had complete medical records after an average follow-up time of 5 (3-13) months. Levels of ESR, CRP, IgG4, IgG, IgE, IgA were 54.0 (36.3, 98.5) mm/h, 26.8 (8.7, 53.0) mg/L, 1.34 (0.55, 3.36) g/L, 16.3 (13.0, 21.1) g/L, 40.5 (31.4, 203.0) IU/mL, 2.51 (1.82, 3.25) g/L at baseline, which all decreased predominantly after treatment. ESR, CRP, IgG4, IgG, IgE and IgA dropped by 38.5 (23.5, 54.3) mm/h (P<0.01), 23.0 (5.5, 52.0) mg/L (P<0.05), 0.92 (0.40, 2.85) g/L (P<0.01), 6.5 (1.7, 9.1) g/L (P<0.05), 23.7 (4.8, 162.0) IU/mL (P<0.05) and 0.77 (0.32, 1.26) g/L (P<0.05), respectively. Size of mass measured by CT/MRI imaging became smaller significantly and hydronephrosis relieved. Conclusion: Onset of RPF is insidious and lack of specific initial symptoms. Corticosteroid based therapy combined with surgical intervention of relieving obstruction is effective.

Key words: Retroperitoneal fibrosis, Hydronephrosis, Glucocorticoids, Surgical procedures, operative, Prognosis

CLC Number: 

  • R656.5

Table 1

Clinical features at presentation in 17 patients with RPF"

Clinical Features n (%)
Gender
Male 12 (70.6)
Female 5 (29.4)
Symptoms
Back pain 9 (52.9)
Abdominal pain 6 (35.3)
Oliguria 2 (11.8)
Lower limb edema 3 (17.6)
Diarrhea 1 (5.9)
Constipation 1 (5.9)
Laboratory studies
Increased CRP 13 (76.5)
Increased ESR 13 (76.5)
Increased IgG4 5 (29.4)
Increased IgG (n=13) 4 (30.8)
Increased IgM (n=13) 0
Increased IgE (n=13) 4 (30.8)
Increased IgA (n=13) 1 (7.7)
Decreased C3 (n=13) 1 (7.7)
Decreased C4 (n=13) 1 (7.7)
Hydronephrosis
Left hydronephrosis 8 (47.1)
Right hydronephrosis 1 (5.9)
Bilateral hydronephrosis 8 (47.1)
Radiographic class
Ⅰ+Ⅱ+Ⅲ 14 (82.4)
Ⅰ+Ⅱ+Ⅲ+Ⅳ 3 (17.6)
Pathological features (n=12)
<10 IgG4+ plasma cells/HPF 6 (50.0)
10-30 IgG4+ plasma cells/HPF 2 (16.7)
>30 IgG4+ plasma cells/HPF 4 (33.3)
IgG4+/IgG+ plasma cell ratio >40% 4 (33.3)
Storiform-type fibrosis 3 (25.0)
Obliterative phlebitis 4 (33.3)

Figure 1

The changes of ESR (A), CRP (B), IgG4 (C), IgG (D), IgE (E) and IgA (F) before and after treatment CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; Ig, immunoglobin."

Figure 2

The changes of axial diameter (A), transverse diameter (B) and anteroposterior diameter (C) in CT scan before and after treatment"

Figure 3

CT demonstrating retroperitoneal fibrosis (A) with resolution after treatment (B)"

[1] Uibu T, Oksa P, Auvinen A, et al. Asbestos exposure as a risk factor for retroperitoneal fibrosis[J]. Lancet, 2004,363(9419):1422-1426.
pmid: 15121404
[2] Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: An open-label randomised controlled trial[J]. Lancet, 2011,378(9788):338-346.
doi: 10.1016/S0140-6736(11)60934-3 pmid: 21733570
[3] Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis: the clinical, laboratory, and radiographic presentation[J]. Medicine (Baltimore), 2009,88(4):202-207.
doi: 10.1097/MD.0b013e3181afc439
[4] Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease[J]. Mod Pathol, 2012,25(9):1181-1192.
doi: 10.1038/modpathol.2012.72 pmid: 22596100
[5] Ormond JK. Bilateral ureteral obstruction due to envelopment and compression by an inflammatory retroperitoneal process[J]. J Urol, 1948,59(6):1072-1079.
doi: 10.1016/s0022-5347(17)69482-5 pmid: 18858051
[6] Zen Y, Onodera M, Inoue D, et al. Retroperitoneal fibrosis: A clinicopathologic study with respect to immunoglobulin G4[J]. Am J Surg Pathol, 2009,33(12):1833-1839.
doi: 10.1097/pas.0b013e3181b72882 pmid: 19950407
[7] Rossi GM, Rocco R, Accorsi Buttini E, et al. Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease[J]. Intern Emerg Med, 2017,12(3):287-299.
doi: 10.1007/s11739-016-1599-z pmid: 28070877
[8] Yamashita K, Haga H, Mikami Y, et al. Degree of IgG4+ plasma cell infiltration in retroperitoneal fibrosis with or without multifocal fibrosclerosis[J]. 2010,52(3):404-409.
[9] Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond's disease: "idiopathic" retroperitoneal fibrosis in the era of IgG4-related disease[J]. Medicine (Baltimore), 2013,92(2):82-91.
doi: 10.1097/MD.0b013e318289610f
[10] Caiafa RO, Vinuesa AS, Izquierdo RS, et al. Retroperitoneal fibrosis: Role of imaging in diagnosis and follow-up[J]. Radiographics, 2013,33(2):535-552.
doi: 10.1148/rg.332125085 pmid: 23479712
[11] George V, Tammisetti VS, Surabhi VR, et al. Chronic fibrosing conditions in abdominal imaging[J]. Radiographics, 2013,33(4):1053-1080.
doi: 10.1148/rg.334125081 pmid: 23842972
[12] Pelkmans LG, Aarnoudse AJ, Hendriksz TR, et al. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis[J]. Nephrol Dial Transplant, 2012,27(7):2819-2825.
doi: 10.1093/ndt/gfr779 pmid: 22273666
[13] van Bommel EF, Siemes C, Hak LE, et al. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone[J]. Am J Kidney Dis, 2007,49(5):615-625.
doi: 10.1053/j.ajkd.2007.02.268 pmid: 17472843
[14] Fry AC, Singh S, Gunda SS, et al. Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: A retrospective study[J]. Nephron Clin Pract, 2008,108(3):c213-220.
doi: 10.1159/000119715 pmid: 18332635
[15] Alberici F, Palmisano A, Urban ML, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis[J]. Ann Rheum Dis, 2013,72(9):1584-1586.
doi: 10.1136/annrheumdis-2013-203545 pmid: 23696631
[16] Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series[J]. Ann Intern Med, 2011,154(1):31-36.
doi: 10.7326/0003-4819-154-1-201101040-00005 pmid: 21200036
[17] Binder M, Uhl M, Wiech T, et al. Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis: a long-term follow-up of 35 patients with chronic periaortitis[J]. Ann Rheum Dis, 2012,71(2):311-312.
doi: 10.1136/annrheumdis-2011-200148 pmid: 21859695
[18] Li KP, Zhu J, Zhang JL, et al. Idiopathic retroperitoneal fibrosis (RPF): Clinical features of 61 cases and literature review[J]. Clin Rheumatol, 2011,30(5):601-605.
doi: 10.1007/s10067-010-1580-6 pmid: 20957401
[19] Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis[J]. J Am Soc Nephrol, 2016,27(7):1880-1889.
doi: 10.1681/ASN.2015101110 pmid: 26860343
[20] Mertens S, Zeegers AG, Wertheimer PA, et al. Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction[J]. Int J Urol, 2014,21(3):283-288.
doi: 10.1111/iju.12234 pmid: 24033464
[21] Cristian S, Cristian M, Cristian P, et al. Management of idiopathic retroperitoneal fibrosis from the urologist's perspective[J]. Ther Adv Urol, 2015,7(2):85-99.
doi: 10.1177/1756287214565637 pmid: 25829952
[1] LI Wei-hao,LI Wei,ZHANG Xue-min,LI Qing-le,JIAO Yang,ZHANG Tao,JIANG Jing-jun,ZHANG Xiao-ming. Comparison of the outcomes between open and hybrid approaches in the treatment of thoracoabdominal aortic aneurysms repair [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 177-181.
[2] SU Jun-qi,SONG Yang,XIE Shang. Analysis of etiological characteristics and establishment of prediction model of postoperative infections in patients undergoing oral squamous cell carcinoma surgery with free flap reconstruction [J]. Journal of Peking University (Health Sciences), 2022, 54(1): 68-76.
[3] Fei WANG,Xiang ZHU,Bei HE,Hong ZHU,Ning SHEN. Spontaneous remission of follicular bronchiolitis with nonspecific interstitial pneumonia: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1196-1200.
[4] Wei-bo GAO,Mao-jing SHI,Hai-yan ZHANG,Chun-bo WU,Ji-hong ZHU. Relationship between marked hyperferritinemia and hemophagocytic lymphohistiocytosis [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 921-927.
[5] Mei-xiang ZHANG,Wen-zhi SHI,Jian-xin LIU,Chun-jian WANG,Yan LI,Wei WANG,Bin JIANG. Clinical characteristics and prognosis of MLL-AF6 positive patients with acute myeloid leukemia [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 915-920.
[6] Hao WU,Li-ping PAN,Heng LIU,Hong-bin WANG,Tai-guo NING,Yong-ping CAO. Effect of posterior tibial slope on the short-term outcome in mobile-bearing unicompartmental knee arthroplasty [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 877-882.
[7] Yan-fang JIANG,Jian WANG,Yong-jian WANG,Jia LIU,Yin PEI,Xiao-peng LIU,Ying-fang AO,Yong MA. Mid-to-long term clinical outcomes and predictors after anterior cruciate ligament revision [J]. Journal of Peking University (Health Sciences), 2021, 53(5): 857-863.
[8] XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin. Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 647-652.
[9] YU Yan-fei,HE Shi-ming,WU Yu-cai,XIONG Sheng-wei,SHEN Qi,LI Yan-yan,YANG Feng,HE Qun,LI Xue-song. Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 640-646.
[10] HAO Han,LIU Yue,CHEN Yu-ke,SI Long-mei,ZHANG Meng,FAN Yu,ZHANG Zhong-yuan,TANG Qi,ZHANG Lei,WU Shi-liang,SONG Yi,LIN Jian,ZHAO Zheng,SHEN Cheng,YU Wei,HAN Wen-ke. Evaluating continence recovery time after robot-assisted radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 697-703.
[11] ZHAO Xun,YAN Ye,HUANG Xiao-juan,DONG Jing-han,LIU Zhuo,ZHANG Hong-xian,LIU Cheng,MA Lu-lin. Influence of deep invasive tumor thrombus on the surgical treatment and prognosis of patients with non-metastatic renal cell carcinoma complicated with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 665-670.
[12] GENG Zhi-yu,GAO Wei-hua,WANG Dong-xin. Clinical outcomes of vocal fold immobility after tracheal intubation [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 337-340.
[13] CHEN Huai-an,LIU Shuo,LI Xiu-jun,WANG Zhe,ZHANG Chao,LI Feng-qi,MIAO Wen-long. Clinical value of inflammatory biomarkers in predicting prognosis of patients with ureteral urothelial carcinoma [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 302-307.
[14] YANG Yang,XIAO Feng,WANG Jin,SONG Bo,LI Xi-hui,ZHANG Shi-jie,HE Zhi-song,ZHANG Huan,YIN Ling. One-stage surgery in patients with both cardiac and non-cardiac diseases [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 327-331.
[15] MENG Zhao-ting,MU Dong-liang. Impact of oliguria during lung surgery on postoperative acute kidney injury [J]. Journal of Peking University (Health Sciences), 2021, 53(1): 188-194.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 456 -458 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 125 -128 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 135 -140 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 158 -161 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 217 -220 .
[6] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 52 -55 .
[7] . [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 109 -111 .
[8] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 297 -301 .
[9] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 505 -515 .
[10] . [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 599 -601 .